CAR-T Breakthroughs in Multiple Myeloma: What’s Changing Patient Outcomes | Mark Schroeder, MD

CAR-T cell therapy has rapidly transformed the treatment landscape for patients with relapsed or refractory myeloma. In this educational session, Dr. Schroeder explains how this innovative cellular immunotherapy works, what researchers are learning from recent clinical trials, and how CAR-T therapies are continuing to improve.